Status:
COMPLETED
Quality Of Life While Receiving Faslodex
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
To study QoL related response, symptom spectrum and severity in disseminated breast cancer patients receiving Faslodex hormonal therapy.
Eligibility Criteria
Inclusion
- Histologic and/or cytological proven breast cancer.
- Patients with metastases of breast cancer ± postmenopausal primary tumor ≥12 months.
- Positive oestrogen receptors (ER+), positive progesterone receptors (PgR+) or unknown hormonal receptors (if duration between surgery and metastasis occurring is not less 2 years) which are indirect confirmation of hormone sensitive tumor.
- ECOG performance status of ≤ 2
- Patient willingness to take part in the programm
- Life expectancy of more than 6 months.
- Patient ability to complete a questionnaire.
Exclusion
- Contraindications for Faslodex therapy
- Other anticancer therapy (chemotherapy, hormonal therapy with other drugs, radiotherapy), except for radiotherapy of sites which are not only measurable or evaluable manifestation of disease.
Key Trial Info
Start Date :
June 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2009
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00643513
Start Date
June 1 2007
End Date
January 1 2009
Last Update
April 22 2009
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
?rasnodar, Russia
2
Research Site
Astrakhan, Russia
3
Research Site
Blagoveshenk, Russia
4
Research Site
Chita, Russia